About: The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats
Creator	Farrar, Jeremy Kimball-Baker, Kathleen Moore, Kristine Osterholm, Michael Ostrowsky, Julie
source	Elsevier; Medline; PMC
abstract	In support of accelerated development of Ebola vaccines from preclinical research to clinical trials, in November, 2014, the Wellcome Trust and the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota established the Wellcome Trust-CIDRAP Ebola Vaccine Team B initiative. This ongoing initiative includes experts with global experience in various phases of bringing new vaccines to market, such as funding, research and development, manufacturing, determination of safety and efficacy, regulatory approval, and vaccination delivery. It also includes experts in community engagement strategies and ethical issues germane to vaccination policies, including eight African scientists with direct experience in developing and implementing vaccination policies in Africa. Ebola Vaccine Team B members have worked on a range of vaccination programmes, such as polio eradication (Africa and globally), development of meningococcal A disease vaccination campaigns in Africa, and malaria and HIV/AIDS vaccine research. We also provide perspective on how this experience can inform future situations where urgent development of vaccines is needed, and we comment on the role that an independent, expert group such as Team B can have in support of national and international public health authorities toward addressing a public health crisis.
has issue date	2015-10-30(xsd:dateTime)
bibo:doi	10.1016/s1473-3099(15)00416-8
bibo:pmid	26526664
has license	no-cc
sha1sum (hex)	12928aeec557f9957cd7490eaa046d1a113e71cb
schema:url	https://doi.org/10.1016/s1473-3099%2815%2900416-8
resource representing a document's title	The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats
has PubMed Central identifier	PMC7106346
has PubMed identifier	26526664
schema:publication	Lancet Infect Dis
resource representing a document's body	covid:12928aeec557f9957cd7490eaa046d1a113e71cb#body_text
is schema:about of	named entity 'DEVELOPMENT' named entity 'support' named entity 'Team B' named entity 'community engagement' named entity 'expert' named entity 'model' named entity 'Vaccine' named entity 'Team B' named entity 'MODEL' named entity 'EBOLA' named entity 'FUTURE' named entity 'PRECLINICAL' named entity 'NOVEMBER' named entity 'GLOBAL' named entity 'WELLCOME TRUST' named entity 'ERADICATION' named entity 'ETHICAL ISSUES' named entity 'VACCINE' named entity 'CLINICAL TRIALS' named entity 'INTERNATIONAL PUBLIC HEALTH' named entity 'INFECTIOUS DISEASE RESEARCH' named entity 'CACY' named entity 'GLOBALLY' named entity 'INCLUDING' named entity 'RESEARCH AND DEVELOPMENT' named entity 'NEEDED' named entity 'REGULATORY' named entity 'SUPPORT' named entity 'GROUP' named entity 'NATIONAL' named entity 'MEMBERS' named entity 'INCLUDES' named entity 'DELIVERY' named entity 'PROVIDE' named entity 'STRATEGIES' named entity 'AUTHORITIES' named entity 'MANUFACTURING' named entity 'INDEPENDENT' named entity 'VACCINE RESEARCH' named entity 'PERSONAL' named entity 'AFRICAN' named entity 'INFORM' named entity 'WHERE' named entity 'CENTER' named entity 'FUNDING' named entity 'AFRICA' named entity 'ONGOING' named entity 'MEDICAL COUNTERMEASURES' named entity 'RAPID' named entity 'PROMOTING' named entity 'PERSPECTIVE' named entity 'PHASES' named entity 'DEVELOPMENT' named entity 'RESEARCH' named entity 'THREATS' named entity 'MALARIA' named entity 'SCIENTISTS' named entity 'VACCINE' named entity 'HAVE' named entity 'RANGE' named entity 'PUBLIC HEALTH' named entity 'MARKET' named entity 'MENINGOCOCCAL' named entity 'DETERMINATION' named entity 'HOW' named entity 'ROLE' named entity 'POLICIES' named entity 'ADDRESSING' named entity 'SAFETY' named entity 'VARIOUS' named entity 'ESTABLISHED' named entity 'DEVELOPING' named entity 'EMERGING INFECTIOUS DISEASE' named entity 'APPROVAL' named entity 'VACCINES' named entity 'POLICY' named entity 'ACCELERATED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software